Peripheral neuropathy in severe COVID ‐19 resolved with therapeutic plasma exchange

Peripheral neuropathies including Guillain ‐Barré syndrome may be linked to life‐threatening COVID‐19. Plasma exchange is a safe rescue therapy in severe COVID‐19 with associated neurological manifestations and thromboinflammation. AbstractPeripheral neuropathies including Guillain ‐Barré syndrome may be linked to life‐threatening COVID‐19. Plasma exchange is a safe rescue therapy in severe COVID‐19 with associated neurological manifestations and thromboinflammation.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research

Related Links:

The human infection of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a public health emergency of international concern that has caused more than 16.8 million new cases and 662,000 deaths as of July 30, 2020. Although coronavirus disease 2019 (COVID-19), which is associated with this virus, mainly affects the lungs, recent evidence from clinical and pathological studies indicates that this pathogen has a broad infective ability to spread to extrapulmonary tissues, causing multiorgan failure in severely ill patients. In this regard, there is increasing preoccupation with the neuroinvasive potenti...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Abstract Guillain-Barré syndrome is an autoimmune peripheral neuropathy and a common cause of neuromuscular paralysis. Preceding infection induces the production of anti-ganglioside (GD) antibodies attacking its own peripheral nerves. Damaged axons fail to regrow and to re-innervate target muscles. In severe peripheral nerve injuries (PNI) such as proximal PNIs that requires long-distance axon regeneration, motor functional recovery is virtually non-exist. In mice, regenerating axons must reach target muscle within 35 days (critical period) to reform functional neuromuscular junctions and regain motor funct...
Source: Brain, Behavior, and Immunity - Category: Neurology Authors: Tags: Brain Behav Immun Source Type: research
Conclusion Our data (1) confirm and extend previous observations that antiparanodal IgG2/3 but not IgG4 antibodies can occur in acute-onset neuropathies manifesting as monophasic GBS, (2) suggest association of IgG3 to a favorable response to IVIg, and (3) lend support to the hypothesis that in some patients, an IgG subclass switch from IgG3 to IgG4 may be the correlate of a secondary progressive or relapsing course following a GBS-like onset.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Autoimmune diseases, All Neuromuscular Disease, Peripheral neuropathy, Guillain-Barre syndrome, Chronic inflammatory demyelinating polyneuropathy Article Source Type: research
The discovery of autoantibodies against paranodal proteins such as neurofascin-155 (NF155), contactin-1 (CNTN1), or contactin-associated protein-1 (CASPR1) in inflammatory neuropathies has led to the description of subsets of patients with specific phenotypic features.1 These antibodies mostly belong to the immunoglobulin G (IgG)4 subclass, but IgG1, IgG2, or IgG3 autoantibodies have also been described.2–4 Different autoantibody isotypes are associated with different effector mechanisms causing nerve damage5,6; testing them may have implications to inform therapeutic choices or to predict prognosis.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Autoimmune diseases, All Neuromuscular Disease, Peripheral neuropathy, Guillain-Barre syndrome, Chronic inflammatory demyelinating polyneuropathy Editorial Source Type: research
SUMMARY: Miller Fisher syndrome, also known as Miller Fisher variant of Guillain-Barré syndrome, is an acute peripheral neuropathy that can develop after exposure to various viral, bacterial, and fungal pathogens. It is characterized by a triad of ophthalmoplegia, ataxia, and areflexia. Miller Fisher syndrome has recently been described in the clinical setting of the novel coronavirus disease 2019 (COVID-19) without accompanying imaging. In this case, we report the first presumptive case of COVID-19–associated Miller Fisher syndrome with MR imaging findings.
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: HEAD & amp; NECK Source Type: research
Conclusion: BRAFi+MEKi combinations share a similar safety profile attributed to class effects, yet concomitantly, these combinations display distinctive effects that can dramatically impact patients’ health. Owing to the limitations of pharmacovigilance studies, some findings warrant further validation. However, the possibility of an increased risk for these events should be considered in patient care.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract Healthy peripheral nerves encounter, with increased frequency, numerous chemical, biological, and biomechanical forces. Over time and with increasing age, these forces collectively contribute to the pathophysiology of a spectrum of traumatic, metabolic, and/or immune-mediated peripheral nerve disorders. The blood-nerve barrier (BNB) serves as a critical first-line defense against chemical and biologic insults while biomechanical forces are continuously buffered by a dense array of longitudinally orientated epineural collagen fibers exhibiting high-tensile strength. As emphasized throughout this Experiment...
Source: Experimental Neurology - Category: Neurology Authors: Tags: Exp Neurol Source Type: research
Patients with nodal/paranodal antibodies represent a specific subgroup of inflammatory peripheral neuropathies, whose clinical presentation with a prolonged subacute phase, additional symptoms such as ataxia and tremor, and poor treatment response to IV immunoglobulin (IVIG) often differs from classic Guillain-Barré syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP).1
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Guillain-Barre syndrome, Chronic inflammatory demyelinating polyneuropathy Clinical/Scientific Notes Source Type: research
At the time of this writing, healthcare systems are facing worldwide the pandemic of the coronavirus severe acute respiratory coronavirus 2 (SARS-COV-2) and its associated disease, named cronavirus disease 19 (COVID-19). This virus is a new human pathogen, and currently, there are no specific treatment options.1 COVID-19 mostly affects the respiratory system, ranging from mild flu-like symptoms to severe pneumonia, but extrarespiratory multisystemic involvement has also been reported.2 Li et al.3 recently described the neuroinvasive potential of COVID-19, but, to our knowledge, no case of acute dysimmune neuropathy has bee...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Autoimmune diseases, Peripheral neuropathy, Guillain-Barre syndrome, COVID-19 Clinical/Scientific Notes Source Type: research
Dengue virus (DENV) and Zika virus (ZIKV) are two mosquito-borne flaviviruses afflicting nearly half of the world population. Human infection by these viruses can either be asymptomatic or manifest as clinical diseases from mild to severe. Despite more cases are presented as self-limiting febrile illness, severe dengue disease can be manifested as hemorrhagic fever and hemorrhagic shock syndrome, and ZIKV infection has been linked to increased incidence of peripheral neuropathy Guillain-Barre syndrome and central neural disease such as microcephaly. The current prevention and treatment of these infectious diseases are eith...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
More News: Brain | General Medicine | Guillain-Barr Syndrome | Neurology | Peripheral Neuropathy